Vertex Pharmaceuticals Q2 FY25: where the revenue came from and where it went
The whole income statement of Vertex Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 5, 2025
Revenue$2.97B
+12% year over year
Gross profit$2.56B
86% margin
Operating profit$1.15B
39% margin
Net profit$1.03B
35% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 2.97 | 100% | +12% |
| Trikafta/Kaftrio | 2.55 | 86% | +4% |
| Manufactured product other | 0.24 | 8% | +20% |
| Alyftrek | 0.16 | 5% | |
| Collaborative & royalty | 0.02 | 1% | |
| Cost of revenue | −0.41 | 14% | |
| Gross profit | 2.56 | 86% margin | +0pp |
| SG&A | −0.43 | 14% | +0pp |
| Other | −0.98 | 33% | +0pp |
| Operating profit | 1.15 | 39% margin | +172pp |
| Other income, net | 0.13 | ||
| Tax | −0.25 | ||
| Net profit | 1.03 | 35% margin | +171pp |
175 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest